Qinec Appoints Jim Horsburgh as Chairman - Gilde Healthcare

Qinec Appoints Jim Horsburgh as Chairman

December 8, 2015

Industry veteran joins digital health company

LONDON – Qinec, a digital health company focused on cloud based Personalised Healthcare Management, today announced that healthcare IT veteran Jim Horsburgh has joined Qinec’s board as a non executive member and been appointed as independent chairman.

Robbie Hughes, CEO at Qinec said:

“Qinec’s Personalised Healthcare Management platform has been adopted by many of the UK’s largest commercial healthcare providers. Jim’s expertise as a chairman of numerous digital health companies will be invaluable in guiding Qinec through the next stage of growth.”

Jim previously served as Chairman of healthcare IT company System C, leading the company through its successful IPO and acquisition by McKesson. He also served as SVP Worldwide Marketing at Visio through its IPO and acquisition by Microsoft, and in business development and marketing roles at CentralPoint Software, Lotus and Olivetti. Jim currently serves as chairman for Insource, a data warehousing automation solution specialising in healthcare, and chairman for Shearwater, a developer of mobile solutions for healthcare. He’s previously served as chairman for ScriptSwitch Ltd. and Triaster Ltd.

Jim Horsburgh said:

“Qinec has had a huge impact on healthcare, challenging the legacy, siloed mentality of healthcare IT by focusing its approach on the orchestration of the patient journey. Qinec has established itself as a trusted agent of change within the industry; its proposition is compelling for patients, providers and payers alike.”

About Qinec

Qinec is a UK-based digital health company providing Personalized Healthcare Management (PHM) solutions. The company’s cloud-based SaaS platform uses real time data to orchestrate the patient journey to achieve optimal outcomes for patients, providers and payers at lower cost. Managing millions of patients a year across Europe, Qinec tailors processes and optimizes clinical and administrative workflows across every specialty of outpatient care. For more information about Qinec please visit www.qinec.com.

Press Contact:

Michele Moore
PR Manager
+44 07507 246 961
Michele.Moore@qinec.com

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007...
June 11, 2025

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term...
June 3, 2025

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
April 28, 2025